Low-Dose Rapamycin In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 23-012373
About this study
The purpose of this observational study is to determine the incidence of elevated levels of inactive ATG-13 and other ATG proteins in patients with ME/CFS, as diagnosed in the clinical practices of clinicians experienced with its identification and management and observe the effects of low dose rapamycin in these patients.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria
- Patients must carry a diagnosis of ME/CFS defined by the international consensus criteria.
- Patients must be between 18 and 65 years old.
- Patients must be able to understand and provide informed consent.
- Treating physicians must recommend oral rapamycin.
Exclusion Criteria
- Patients must not be pregnant or have confounding illnesses such as HIV, congestive heart failure, chronic kidney disease, malignancy, etc. or others that could potentially explain the presence of chronic fatigue and CFS-related symptoms.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility last updated 11/28/23. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Stephanie Grach, M.D., M.S. |
Contact us for the latest status |
|
More information
Publications
Publications are currently not available